Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Blinded, Controlled Phase I/Ⅱ Clinical Trial Evaluating the Safety and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) for Healthy Individuals Aged 40 Years and Above

NCT06932523 is registered in ClinicalTrials.gov with Shanghai Institute Of Biological Products as lead sponsor.

NCT NCT06932523
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06932523 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Blinded, Controlled Phase I/Ⅱ Clinical Trial Evaluating the Safety and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) for Healthy Individuals Aged 40 Years and Above
Lead sponsor
Shanghai Institute Of Biological Products
Phase
Phase 1/2
Overall status
Recruiting
Start date
April 4, 2025
Completion date
December 31, 2027
Enrollment
645 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

herpes zoster (hz)